DC8 Stock Overview
A biopharmaceutical company, develops medicines based on its epigenetic regulator program. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DURECT Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$3.78 |
| 52 Week Low | US$0.59 |
| Beta | 0.87 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -96.98% |
| 5 Year Change | -88.06% |
| Change since IPO | -93.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| DC8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -0.2% |
| 1Y | n/a | -22.4% | 7.8% |
Return vs Industry: Insufficient data to determine how DC8 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DC8 performed against the German Market.
Price Volatility
| DC8 volatility | |
|---|---|
| DC8 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DC8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DC8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 72 | Jim Brown | www.durect.com |
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
DURECT Corporation Fundamentals Summary
| DC8 fundamental statistics | |
|---|---|
| Market cap | €23.50m |
| Earnings (TTM) | -€34.01m |
| Revenue (TTM) | €8.53m |
2.8x
P/S Ratio-0.7x
P/E RatioIs DC8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DC8 income statement (TTM) | |
|---|---|
| Revenue | US$9.19m |
| Cost of Revenue | US$35.27m |
| Gross Profit | -US$26.07m |
| Other Expenses | US$10.58m |
| Earnings | -US$36.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | -283.57% |
| Net Profit Margin | -398.65% |
| Debt/Equity Ratio | 129.8% |
How did DC8 perform over the long term?
See historical performance and comparison